AlphAIAlphAI — Financial news for AI agents
247wallst.com$CAH

Cardinal Health Q1 2027: EPS beats by 11%, CVS deal secured

Cardinal Health reported Q1 2027 adjusted EPS of $3.26, beating estimates by 11%. Revenue was $67.51B, up 5.5% YoY. The company secured a deal with CVS Health and raised fiscal 2027 EPS guidance to $12.80-$13.00. Management also completed a $500M share repurchase program.

Original reporting
247wallst.com
Published Nov 5, 2026, 11:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Cardinal Health Q1 2027: EPS beats by 11%, CVS deal secured — source image
Source · 247wallst.com
Decision brief

The 30-second read

$CAHBullishHigh
01

Why it matters

The earnings beat and guidance raise could trigger a short‑cover rally and attract new buying interest.

02

Market read

Strong earnings and a secured CVS contract provide a clear catalyst for CAH stock, making the news highly relevant for traders.

03

What to watch

Potential headwinds from generic drug pricing pressure and integration risk of the upcoming AdaptHealth acquisition.

Relevance 9/10Novelty 9/10Timing: post‑earnings release

Background

Cardinal Health is a leading U.S. drug distributor; CVS Health is its largest customer.

Company-level read

Ticker impact

$CAHBullishHigh confidence
Context

Cardinal Health posted Q1 2027 earnings beat and raised FY2027 EPS guidance to $12.80‑$13.00.

Expected impact

likely upward pressure as investors price in higher earnings outlook

Evidence & confidence

Strong earnings, revenue beat, and a renewed CVS distribution agreement reduce risk and support higher multiples.

Market effects

Sector

Pharmaceutical distribution sector may see broader optimism as a major customer contract is secured.

Regional

U.S. healthcare distribution stocks could benefit from the reaffirmed CVS partnership.

Global

Limited to U.S. market; no direct global macro effect.

Counterpoint

What could challenge this read

If the CVS contract renewal is only a letter of intent, execution risk remains and the guidance may be overly optimistic.

Key entities

  • company
    Cardinal Health

    U.S. drug distributor reporting Q1 2027 results.

  • company
    CVS Health

    Largest customer of Cardinal Health, signing a renewal LOI.

Read at source← All news

StoryCardinal Health reports Q1 FY2027 results and lifts FY2027 non‑GAAP EPS outlook

Also covered by

6 outlets

Related articles

$CAHHighAI 8/10

Cardinal Health beats estimates, raises guidance

Cardinal Health (NYSE:CAH) reported Q1 earnings of $3.26 per share, beating estimates by $0.31, with revenue up 5% YoY to $67.5B. The company raised its FY2027 EPS guidance to $12.80-$13.00. Shares rose 2.70% in pre-market trading. Growth was driven by the Pharmaceutical and Specialty Solutions segment, with revenue up 6% and profit up 17%.

investing.com
$CAHHighAI 9/10

Cardinal: Fiscal Q1 Earnings Snapshot

Cardinal Health (CAH) reported fiscal Q1 net income of $554M, or $2.38 per share, beating analyst expectations of $2.92 per share. Revenue was $67.51B, exceeding forecasts of $66.96B. The company expects full-year earnings between $12.80 and $13 per share. CAH shares have risen 27% YTD and 34% over the past year.

finance.yahoo.com
$CAHHighAI 9/10

Cardinal Health Reports First Quarter Fiscal Year 2027 Results and Raises Outlook

CARDINAL HEALTH INC (CAH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Cardinal Health Reports First Quarter Fiscal Year 2027 Results and Raises Outlook • First quarter revenue increased 5% to $67.5 billion • GAAP 1 operating earnings increased 13% to $753 million; GAAP diluted EPS increased 27% to $2.38 • Non-GAAP

SEC EDGAR 8-K